BeOne Medicines (BEIGF) Other Operating Expenses (2017 - 2023)

BeOne Medicines (BEIGF) has reported Other Operating Expenses for 7 consecutive years, with $188000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Other Operating Expenses fell 99.74% year-over-year to $188000.0 in Q2 2023; TTM through Mar 2024 was $188000.0, a 100.29% increase from a year earlier, with the FY2021 full-year figure at $750000.0, down 98.95% from the prior year.
• Other Operating Expenses was $188000.0 for Q2 2023 at BeOne Medicines, up from $187000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $76.7 million in Q3 2022 and troughed at -$213.5 million in Q4 2022.
• A 5-year average of $8.1 million and a median of $19.4 million in 2019 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses surged 229.08% in 2019 and slumped 646.29% in 2021, its largest moves.
• Over 5 years, Other Operating Expenses stood at $18.3 million in 2019, then climbed by 16.11% to $21.3 million in 2020, then tumbled by 646.29% to -$116.2 million in 2021, then tumbled by 83.79% to -$213.5 million in 2022, then soared by 100.09% to $188000.0 in 2023.
• The last three Other Operating Expenses figures came in at $188000.0 (Q2 2023), $187000.0 (Q1 2023), and -$213.5 million (Q4 2022), per Business Quant data.